GSK, Novartis to close vax deal next week; NICE rejects Dendreon's Provenge;

> GlaxoSmithKline ($GSK) and Novartis ($NVS) are preparing to close their multi-billion-dollar asset swap--which will send most of Novartis' vaccines unit to Glaxo--in the week beginning March 2. Report

> The U.K.'s cost watchdogs have shot down Dendreon's ($DNDN) Provenge, the price is "too high for the benefit it may provide to patients." Report

> Protein Sciences has added Cardinal Health ($CAH) and McKesson ($MCK) as distributors for its flu vaccine, Flublok. Release

> Maryland's Sanaria is leveraging a logistics partnership with Cryoport to support its malaria vaccine development. More

> A centralized statewide reminder system for immunizations may be a more reliable way to increase overall vaccination rates, a new report says. More

And Finally... Pro-vaccine Facebook ($FB) founder Mark Zuckerberg is urging Facebook users to read a book about why people fear vaccination. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.